CN1504208A - Gingko drop pill for prevention and treatment of cardiovascular and cerebrovascular disease - Google Patents
Gingko drop pill for prevention and treatment of cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN1504208A CN1504208A CNA021359369A CN02135936A CN1504208A CN 1504208 A CN1504208 A CN 1504208A CN A021359369 A CNA021359369 A CN A021359369A CN 02135936 A CN02135936 A CN 02135936A CN 1504208 A CN1504208 A CN 1504208A
- Authority
- CN
- China
- Prior art keywords
- parts
- gingko
- drop pill
- preventing
- cerebrovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a gingko drop pill for prevention and cure of cardio-cerebrovascular diseases, which mainly solves the problem of slow effect caused by the slow absorption rate of the ginkgo tablet during the disease treatment process. The drop pill comprises the following constituents with parts by weight, ginkgo leaf extract 1-60 parts, red sage root extract 0-60 parts, ground substance 20-80 parts. The content of active bilobanone ingredient in the medicament is 1-60%, the content of bilobalide is 0.5-6%.
Description
Technical field
The present invention relates to the medicine of a kind of prevention and treatment cardiovascular and cerebrovascular disease, particularly a kind of is the drop pill type Chinese medicine preparation of main effective ingredient by Folium Ginkgo extract.
Background technology
Ginkgetin and bilobalide in the Folium Ginkgo extract have dilating effect to arteries; be used for the treatment of coronary blood supply insufficiency due to arteriosclerosis and the hypertension, angina pectoris, myocardial infarction, cerebral embolism, cerebral vasospasm and because of bad caused other illness of arteries blood supply; Radix Salviae Miltiorrhizae extract has protective effect to myocardial ischemia, is the active drug of treatment cardiovascular disease.The form of Chinese drug of being made by Folium Ginkgo extract at present has injection, tablet and oral liquid, but does not have drop pill, and the speed that aforementioned dosage form is absorbed by the body is all slower, thereby onset is also not ideal enough after the medication.
Summary of the invention
The object of the present invention is to provide a kind of absorption better, the onset of expansion cardiovascular and cerebrovascular vessel is drop pill type medicine faster.Solution of the present invention is based on Chinese medicine to cardiovascular and cerebrovascular disease and pathogenetic understanding of complication and Therapeutic Principle; the invention of tracking modern pharmacological research; from plant class Chinese herbal medicine, filter out the dilative Folium Ginkgo extract of arteries; there is protective effect to have the Radix Salviae Miltiorrhizae extract of blood circulation promoting and blood stasis dispelling function to myocardial ischemia; be equipped with substrate such as Polyethylene Glycol or sodium stearate, glycerol-gelatin, carbamide-poly-rafter acid, tristerin, the dosage form of this medicine is for being beneficial to the drop pill of absorption especially.The content of ginkgetin accounts for 1-60% in this kind gingko drop pill, and the content of bilobalide accounts for 0.5-8%, and the content of TANSHINONES accounts for 0-60%.The pharmacological action of gingko drop pill is as follows: 1. remove free radical, suppress cell membrane lipid oxidation reaction; 2. prevent thrombosis and antiplatelet aggregation; 3. to exsomatizing and, protective effect being arranged all at the cardiac disorder that body regional myocardial ischemia and loose heart regional myocardial ischemia cause; 4. enhancing erythrocyte deformability, blood viscosity lowering; 5. reduce the generation of lipid peroxide, improve the erythrocyte sod activity; 6. brain blood circulation and brain cell metabolism there are improvement and facilitation preferably.
Gingko drop pill has better curative effect for the coronary blood supply insufficiency of preventing and treating arteriosclerosis and caused by hypertension, angina pectoris, myocardial infarction, cerebral embolism, cerebral vasospasm etc.The drop pill granule is tiny, and drop pill is placed sublingual administration, absorbs sooner, can reach the blood maximum concentration after 10 minutes.
The preparation method of this kind gingko drop pill is: after getting Folium Ginkgo extract and Radix Salviae Miltiorrhizae extract and be crushed to 80-100 order granularity by prescription, with the substrate mixing, be heated to 80-100 ℃ of said medicine and enter molten condition, stir, adopt under the 60-80 ℃ of keeping warm mode craft or machinery with spice in the rustless steel nib splashes into 15 ℃ liquid paraffin, cooling forming at room temperature, the demoulding promptly after the shaping.
Oar method according to two appendix 60 of Chinese Pharmacopoeia nineteen ninety version is made contrast mensuration to the present invention and existing Semen Ginkgo sheet dissolution rate: get 1 of Semen Ginkgo sheet, 5 of gingko drop pills, 500ml makes dissolve medium with 0.01mol/L hydrochloric acid, rotating speed 60r/min, 37 ± 0.5 ℃ of temperature.Respectively 3,6,9,12,15min timing sampling 8ml immediately through the membrane filtration of 0.8 μ m, and adds 37 ℃, 0.01mol/L hydrochloric acid 8ml immediately, gets filtrate 5ml, after pressing the processing of sample enrichment method, sample introduction 10 μ l carry out the high-performance liquid chromatogram determination flavonoid of ginkgo biloba.With the stripping quantity of two kinds of each time points of dosage form recording, calculate the accumulation stripping percentage ratio of tablet and drop pill.The accumulation stripping percentage ratio of two kinds of dosage forms sees the following form:
| Dosage form | 3 minutes | 6 minutes | 9 minutes | 12 minutes | 15 minutes |
| The Semen Ginkgo tablet | ????12.45 | ????20.23 | ????25.78 | ????30.01 | ????32.67 |
| Gingko drop pill | ????35.22 | ????60.56 | ????90.33 | ????100.00 | ????100.00 |
Gingko drop pill stripping of 100% in the time of 12 minutes as seen from the above table, and a Semen Ginkgo tablet stripping 30.01%, fast 3 times of gingko drop pills than Semen Ginkgo sheet dissolution rate.
This medicine dropped into clinical trial in 2000, according to 890 routine patients' case history statistics, total effective rate reaches 90%, and the patient reflects that generally gingko drop pill has easy absorption, instant effect, characteristics evident in efficacy.Now show with following case:
The season * *, the man, 52 years old, coronary heart disease with hypertension, systolic pressure were higher than 24.0Kpa (180mmHg), and conscious uncomfortable in chest, dizzy, Wry Neck was taken this medicine after 20 days, uncomfortable in chestly obviously alleviated, and systolic pressure is reduced to 18.8Kpa (141mmHg), and the back of taking medicine does not have other discomforts.
The Wei * *, the woman, 63 years old, hyperlipemia was with diabetes, malaise, numb limbs and tense tendons was taken medicine 18 days, and feeling of numbness disappears, and the asthenia improving situation is tested low-density lipoprotein cholesterol through sanguification and is reduced to 2.5mmol/L.
Chinese mugwort * *, the man, 66 years old, gingko drop pill was taken in the repeatedly concurrent angina pectoris of coronary heart disease during pareordia dull pain, angina pectoris in 10 minutes disappears, after take medicine continuously around, heart is no abnormal.
Liu * *, the man, 70 years old, hypertension once had the apoplexy history, left ventricular hypertrophy, systolic pressure are higher than 21.3Kpa (160mmHg), and private prosecution dizziness, headache, tinnitus were taken medicine 22 days, above-mentioned discomfort obviously reduces, and sleep takes a turn for the better, and blood pressure stabilization is at 18.6/12.0Kpa (140/90mmHg).
Specific embodiment:
1, get raw material by following weight proportion:
1 part of Folium Ginkgo extract, 20 parts of substrate.
2, get raw material by following weight proportion:
1 part of Folium Ginkgo extract, 55 parts of substrate.
3, get raw material by following weight proportion:
1 part of Folium Ginkgo extract, 80 parts of substrate.
4, get raw material by following weight proportion:
1 part of Folium Ginkgo extract, 30 parts of Radix Salviae Miltiorrhizae extracts, 20 parts of substrate.
5, get raw material by following weight proportion:
1 part of Folium Ginkgo extract, 40 parts of Radix Salviae Miltiorrhizae extracts, 50 parts of substrate.
6, get raw material by following weight proportion:
2 parts of Folium Ginkgo extract, 30 parts of Radix Salviae Miltiorrhizae extracts, 80 parts of substrate.
7, get raw material by following weight proportion:
2 parts of Folium Ginkgo extract, 60 parts of Radix Salviae Miltiorrhizae extracts, 20 parts of substrate.
8, get raw material by following weight proportion:
3 parts of Folium Ginkgo extract, 55 parts of Radix Salviae Miltiorrhizae extracts, 45 parts of substrate.
9, get raw material by following weight proportion:
4 parts of Folium Ginkgo extract, 55 parts of Radix Salviae Miltiorrhizae extracts, 80 parts of substrate.
10, get raw material by following weight proportion:
30 parts of Folium Ginkgo extract, 20 parts of substrate.
11, get raw material by following weight proportion:
30 parts of Folium Ginkgo extract, 2 parts of Radix Salviae Miltiorrhizae extracts, 50 parts of substrate.
12, get raw material by following weight proportion:
40 parts of Folium Ginkgo extract, 3 parts of Radix Salviae Miltiorrhizae extracts, 80 parts of substrate.
13, get raw material by following weight proportion:
30 parts of Folium Ginkgo extract, 30 parts of Radix Salviae Miltiorrhizae extracts, 20 parts of substrate.
14, get raw material by following weight proportion:
30 parts of Folium Ginkgo extract, 30 parts of Radix Salviae Miltiorrhizae extracts, 40 parts of substrate.
15, get raw material by following weight proportion:
30 parts of Folium Ginkgo extract, 30 parts of Radix Salviae Miltiorrhizae extracts, 80 parts of substrate.
16, get raw material by following weight proportion:
25 parts of Folium Ginkgo extract, 60 parts of Radix Salviae Miltiorrhizae extracts, 20 parts of substrate.
17, get raw material by following weight proportion:
30 parts of Folium Ginkgo extract, 60 parts of Radix Salviae Miltiorrhizae extracts, 50 parts of substrate.
18, get raw material by following weight proportion:
30 parts of Folium Ginkgo extract, 60 parts of Radix Salviae Miltiorrhizae extracts, 80 parts of substrate.
19, get raw material by following weight proportion:
60 parts of Folium Ginkgo extract, 20 parts of substrate.
20, get raw material by following weight proportion:
60 parts of Folium Ginkgo extract, 50 parts of substrate.
21, get raw material by following weight proportion:
60 parts of Folium Ginkgo extract, 80 parts of substrate.
22, get raw material by following weight proportion:
60 parts of Folium Ginkgo extract, 30 parts of Radix Salviae Miltiorrhizae extracts, 20 parts of substrate.
23, get raw material by following weight proportion:
60 parts of Folium Ginkgo extract, 30 parts of Radix Salviae Miltiorrhizae extracts, 50 parts of substrate.
24, get raw material by following weight proportion:
60 parts of Folium Ginkgo extract, 25 parts of Radix Salviae Miltiorrhizae extracts, 80 parts of substrate.
25, get raw material by following weight proportion:
50 parts of Folium Ginkgo extract, 60 parts of Radix Salviae Miltiorrhizae extracts, 20 parts of substrate.
26, get raw material by following weight proportion:
50 parts of Folium Ginkgo extract, 60 parts of Radix Salviae Miltiorrhizae extracts, 40 parts of substrate.
27, get raw material by following weight proportion:
50 parts of Folium Ginkgo extract, 60 parts of Radix Salviae Miltiorrhizae extracts, 80 parts of substrate.
The production method of gingko drop pill is as follows:
Folium Ginkgo extract and Radix Salviae Miltiorrhizae extract are all buied from the market, after getting Folium Ginkgo extract and Radix Salviae Miltiorrhizae extract and be crushed to 80-100 order granularity by prescription, with the substrate mixing, be heated to 80-100 ℃ of said medicine and enter molten condition, stir, adopt under the 60-80 ℃ of keeping warm mode craft or machinery with spice in the rustless steel nib splashes into 15 ℃ liquid paraffin, cooling forming at room temperature, the back demoulding promptly after the shaping.
The heavy 1-30mg of the every ball of gingko drop pill.Day obeys 3 times, each 200-500mg.
Claims (7)
1, a kind of gingko drop pill of preventing and treating cardiovascular and cerebrovascular disease is characterized in that it is made up of the raw material components of following parts by weight:
Folium Ginkgo extract 1-60 part Radix Salviae Miltiorrhizae extract 0-60 part
Substrate 20-80 part;
Folium Ginkgo extract and Radix Salviae Miltiorrhizae extract are pulverized, with the substrate mixing, be heated to molten condition, adopt under the 60-80 ℃ of keeping warm mode craft or machinery with spice in the rustless steel nib splashes into 15 ℃ liquid paraffin, cooling forming at room temperature, the back demoulding promptly after the shaping.
2, a kind of gingko drop pill of preventing and treating cardiovascular and cerebrovascular disease according to claim 1 is characterized in that the content of the effective ingredient ginkgetin of this medicine accounts for 1-60%, and the content of bilobalide accounts for 0.5-8%, and the content of TANSHINONES accounts for 0-60%.
3, a kind of gingko drop pill of preventing and treating cardiovascular and cerebrovascular disease according to claim 1, it is characterized in that: described substrate is Polyethylene Glycol.
4, a kind of gingko drop pill of preventing and treating cardiovascular and cerebrovascular disease according to claim 1, it is characterized in that: described substrate is sodium stearate.
5, a kind of gingko drop pill of preventing and treating cardiovascular and cerebrovascular disease according to claim 1, it is characterized in that: described substrate is glycerol-gelatin.
6, a kind of medicine of preventing and treating cardiovascular and cerebrovascular vessel according to claim 1 is characterized in that: described substrate is carbamide-poly-rafter acid.
7, a kind of gingko drop pill of preventing and treating cardiovascular and cerebrovascular disease according to claim 1, it is characterized in that: described substrate is tristerin.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021359369A CN1263472C (en) | 2002-11-29 | 2002-11-29 | Gingko drop pill for prevention and treatment of cardiovascular and cerebrovascular disease |
| AU2003292880A AU2003292880A1 (en) | 2002-11-29 | 2003-11-28 | A drop pill of treating and preventing from cardio-cerebral diseases and the process of producing thereof |
| PCT/CN2003/001014 WO2004050107A1 (en) | 2002-11-29 | 2003-11-28 | A drop pill of treating and preventing from cardio-cerebral diseases and the process of producing thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021359369A CN1263472C (en) | 2002-11-29 | 2002-11-29 | Gingko drop pill for prevention and treatment of cardiovascular and cerebrovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1504208A true CN1504208A (en) | 2004-06-16 |
| CN1263472C CN1263472C (en) | 2006-07-12 |
Family
ID=32400066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021359369A Expired - Fee Related CN1263472C (en) | 2002-11-29 | 2002-11-29 | Gingko drop pill for prevention and treatment of cardiovascular and cerebrovascular disease |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1263472C (en) |
| AU (1) | AU2003292880A1 (en) |
| WO (1) | WO2004050107A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872099B (en) * | 2005-06-01 | 2010-09-29 | 天津天士力制药股份有限公司 | Medication for treating cardiovascular diseases, and cerebrovascular disease |
| CN102058629A (en) * | 2010-12-31 | 2011-05-18 | 浙江康恩贝制药股份有限公司 | Method for producing ginkgo biloba leaf tablets by high-speed tablet press |
| CN101156893B (en) * | 2005-02-07 | 2012-02-01 | 贵阳云岩西创药物科技开发有限公司 | Detection method of apricot red injection |
| CN103655673A (en) * | 2013-12-24 | 2014-03-26 | 湖南麓山天然植物制药有限公司 | Compound gingko dropping pill and preparation method thereof |
| CN108066645A (en) * | 2017-12-14 | 2018-05-25 | 芜湖市诺康生物科技有限公司 | A kind of preparation method of ginkgo leaf capsule of red sage root |
| CN110946898A (en) * | 2019-12-19 | 2020-04-03 | 西藏越星泰达医药科技有限责任公司 | Dripping pill preparation |
| US11135199B2 (en) | 2016-08-29 | 2021-10-05 | Neurodawn Pharmaceutical Co., Ltd. | Sublingual pharmaceutical compositions of edaravone and (+)-2-borneol |
| CN114010703A (en) * | 2021-11-22 | 2022-02-08 | 长沙医学院 | Chinese herbal medicine composition and preparation and application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954826A (en) * | 2005-10-26 | 2007-05-02 | 上海生物芯片有限公司 | Use of ginkgo biloba extract in cholesterol reducing |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116532A (en) * | 1994-08-11 | 1996-02-14 | 邓忠元 | Process for producing extract of gingko leaves |
| CN1165638A (en) * | 1997-01-08 | 1997-11-26 | 贵州银信保健品有限公司 | Beverage prepared from extraction of ginkgo leaves |
| CN1167143A (en) * | 1997-06-20 | 1997-12-10 | 山东农业大学 | Ginkgo Leaves health care liquor |
| CN1238191A (en) * | 1998-06-08 | 1999-12-15 | 扬州四菱食品有限公司 | Gingkocapsule |
| CN1240654A (en) * | 1998-06-25 | 2000-01-12 | 刘方明 | Compound gingko-red sage tablet and its preparing process |
| CN1199664C (en) * | 2001-11-23 | 2005-05-04 | 曹柱 | Chinese medicine for treating cardiovascular and cerebrovascular diseases and its preparing process |
| CN1176707C (en) * | 2002-11-19 | 2004-11-24 | 贵州君之堂制药有限公司 | Ginkgo-leaf small pills |
| CN100569244C (en) * | 2003-06-02 | 2009-12-16 | 沈阳药科大学 | Folium Ginkgo extract self-emulsifying soft capsule and preparation method thereof |
-
2002
- 2002-11-29 CN CNB021359369A patent/CN1263472C/en not_active Expired - Fee Related
-
2003
- 2003-11-28 AU AU2003292880A patent/AU2003292880A1/en not_active Abandoned
- 2003-11-28 WO PCT/CN2003/001014 patent/WO2004050107A1/en not_active Application Discontinuation
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156893B (en) * | 2005-02-07 | 2012-02-01 | 贵阳云岩西创药物科技开发有限公司 | Detection method of apricot red injection |
| CN1872099B (en) * | 2005-06-01 | 2010-09-29 | 天津天士力制药股份有限公司 | Medication for treating cardiovascular diseases, and cerebrovascular disease |
| CN102058629A (en) * | 2010-12-31 | 2011-05-18 | 浙江康恩贝制药股份有限公司 | Method for producing ginkgo biloba leaf tablets by high-speed tablet press |
| CN102058629B (en) * | 2010-12-31 | 2015-09-02 | 浙江康恩贝制药股份有限公司 | Be suitable for the method that tablets of Ginkgo biloba L produced by high speed tablet press |
| CN103655673A (en) * | 2013-12-24 | 2014-03-26 | 湖南麓山天然植物制药有限公司 | Compound gingko dropping pill and preparation method thereof |
| US11135199B2 (en) | 2016-08-29 | 2021-10-05 | Neurodawn Pharmaceutical Co., Ltd. | Sublingual pharmaceutical compositions of edaravone and (+)-2-borneol |
| CN108066645A (en) * | 2017-12-14 | 2018-05-25 | 芜湖市诺康生物科技有限公司 | A kind of preparation method of ginkgo leaf capsule of red sage root |
| CN110946898A (en) * | 2019-12-19 | 2020-04-03 | 西藏越星泰达医药科技有限责任公司 | Dripping pill preparation |
| CN114010703A (en) * | 2021-11-22 | 2022-02-08 | 长沙医学院 | Chinese herbal medicine composition and preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004050107A1 (en) | 2004-06-17 |
| CN1263472C (en) | 2006-07-12 |
| AU2003292880A1 (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050037094A1 (en) | Composition for heart disease, its active ingredients, method to prepare same and uses thereof | |
| CN102038745B (en) | Hypolipidemic traditional Chinese medicine | |
| CN1263472C (en) | Gingko drop pill for prevention and treatment of cardiovascular and cerebrovascular disease | |
| CN101822789B (en) | Hypotensor treating essential hypertension | |
| CN1927300A (en) | Chinese medicine composition for treating skin pruritus | |
| CN1853702A (en) | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method | |
| CN1304769A (en) | Blood-cleaning pill | |
| CN1927279A (en) | Chinese medicine composition for treating skin disease | |
| CN1850167A (en) | Thirsty-relieving blood-sugar-reducing dropping pills and preparing method | |
| CN1067901C (en) | Drug for curing migraine and its preparing method | |
| CN1781516A (en) | Method for preparing piper laetispicum extract, extract and its use | |
| CN1565524A (en) | Medicine for treating senile dementia and its preparing process | |
| CN1857599A (en) | Medicine for lowering blood sugar, blood fat and blood pressure, raising blood flow rate and raising immunity and its preparing method | |
| CN1814188A (en) | Vitaminc lonicera and forsythia capsule and preparing method | |
| CN1520879A (en) | Chinese caterpillar fungus ginseng dan drop pills and preparing process thereof | |
| CN1876087A (en) | A medicament for treating tension headache and preparation method thereof | |
| CN1872099A (en) | Medication for treating cardiovascular diseases, and cerebrovascular disease | |
| CN1559469A (en) | Prepn. method for freezing-drying powder injection for treating cardiovascular disease | |
| CN1672722A (en) | Heart-nourishing and tranquilizing medicine and its prepn process | |
| CN112206279B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and preparation method and application thereof | |
| CN1742860A (en) | Enema for treating pelvic inflammation and preparing method | |
| CN1091382C (en) | Compound Lingxian headache-treating capsule and its preparation | |
| CN1857370A (en) | Notoginseng hemostatic and its preparing method | |
| CN105998758A (en) | Preparation methods of traditional Chinese medicinal composition for treating hypertension and preparation of traditional Chinese medicinal composition | |
| CN1872250A (en) | Composition of medication for treating headache |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160503 Address after: 100081 L, Les Loges Du Park Hotel, Old Summer Palace West Road, Beijing, 301 Patentee after: Zhang Yong Address before: 100081 L, Les Loges Du Park Hotel, Old Summer Palace West Road, Beijing, 301 Patentee before: Zhang Yong Patentee before: Wang Meiling |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060712 Termination date: 20201129 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |